ES2078455T3 - 3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas. - Google Patents

3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas.

Info

Publication number
ES2078455T3
ES2078455T3 ES91308324T ES91308324T ES2078455T3 ES 2078455 T3 ES2078455 T3 ES 2078455T3 ES 91308324 T ES91308324 T ES 91308324T ES 91308324 T ES91308324 T ES 91308324T ES 2078455 T3 ES2078455 T3 ES 2078455T3
Authority
ES
Spain
Prior art keywords
quinazolinones
cck
pharmaceutical
antagonists
aril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91308324T
Other languages
English (en)
Inventor
Jefferson Ray Mccowan
Kenneth Jeff Thrasher
Melvin Joseph Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2078455T3 publication Critical patent/ES2078455T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE HA ENCONTRADO QUE NUEVAS QUINAZOLINONAS SUSTITUIDAS EXHIBEN UNA UNION ESPECIFICA A RECEPTORES DE COLECISTOGUININA (CCK) EN EL CEREBRO Y/O LUGAR PERIFERICO TAL COMO EL PANCREAS Y EL ILEO. LAS QUINAZOLINONAS SON ANTAGONISTAS RECEPTORES DE CCK Y ENCUENTRAN APLICACIONES TERAPEUTICAS EN EL TRATAMIENTO DE DISFUNCIONES GASTROINTESTINALES Y DEL SISTEMA NERVIOSO CENTRAL, Y SON UTILES PARA LA REGULACION DEL APETITO EN MAMIFEROS. SE DESCRIBEN TAMBIEN FORMULAS FARMACEUTICAS PARA TALES INDICACIONES.
ES91308324T 1990-09-13 1991-09-12 3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas. Expired - Lifetime ES2078455T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/581,943 US5075313A (en) 1990-09-13 1990-09-13 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof

Publications (1)

Publication Number Publication Date
ES2078455T3 true ES2078455T3 (es) 1995-12-16

Family

ID=24327210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91308324T Expired - Lifetime ES2078455T3 (es) 1990-09-13 1991-09-12 3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas.

Country Status (20)

Country Link
US (1) US5075313A (es)
EP (1) EP0475755B1 (es)
JP (1) JPH04247080A (es)
KR (1) KR920006350A (es)
CN (1) CN1059722A (es)
AU (1) AU641043B2 (es)
CA (1) CA2050994A1 (es)
CZ (1) CZ279774B6 (es)
DE (1) DE69113379T2 (es)
ES (1) ES2078455T3 (es)
FI (1) FI914262A7 (es)
HU (1) HUT59128A (es)
IE (1) IE913217A1 (es)
IL (1) IL99402A0 (es)
MX (1) MX9101035A (es)
NO (1) NO913579L (es)
NZ (1) NZ239712A (es)
PT (1) PT98915A (es)
YU (1) YU151691A (es)
ZA (1) ZA917149B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340801A (en) * 1991-05-08 1994-08-23 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having cholecystokinin and gastrin antagonistic properties
US5204354A (en) * 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
CA2097208C (en) * 1992-06-05 2005-02-08 Raymond Baker The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
BRPI0412684A (pt) * 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
GB0319126D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
AU2005311826A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
EP1819673A2 (en) * 2004-11-30 2007-08-22 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
CA2621406A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
CA2621275A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
US20100152209A1 (en) * 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
EP4574822A3 (en) 2020-01-29 2025-08-27 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
JPH03503650A (ja) * 1988-04-05 1991-08-15 アボツト・ラボラトリーズ Ｃｃｋアンタゴニストとしてのトリプトファン誘導体

Also Published As

Publication number Publication date
ZA917149B (en) 1992-05-27
EP0475755B1 (en) 1995-09-27
FI914262L (fi) 1992-03-14
NZ239712A (en) 1993-06-25
MX9101035A (es) 1992-05-04
KR920006350A (ko) 1992-04-27
DE69113379T2 (de) 1996-03-21
FI914262A0 (fi) 1991-09-10
CN1059722A (zh) 1992-03-25
NO913579D0 (no) 1991-09-11
HUT59128A (en) 1992-04-28
PT98915A (pt) 1992-08-31
IE913217A1 (en) 1992-02-25
DE69113379D1 (de) 1995-11-02
EP0475755A1 (en) 1992-03-18
US5075313A (en) 1991-12-24
CA2050994A1 (en) 1992-03-14
IL99402A0 (en) 1992-08-18
CZ279774B6 (cs) 1995-06-14
YU151691A (sh) 1994-01-20
AU8382991A (en) 1992-03-19
CS279991A3 (en) 1992-04-15
FI914262A7 (fi) 1992-03-14
HU912921D0 (en) 1992-01-28
AU641043B2 (en) 1993-09-09
NO913579L (no) 1992-03-16
JPH04247080A (ja) 1992-09-03

Similar Documents

Publication Publication Date Title
MX9302888A (es) 1,2,3,4-tetrahidroisoquinolinas substituidas con propiedades antagonistas del receptor de angiotensina ii.
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
ES2150482T3 (es) Pirazolopirimidinas como antagonistas del factor liberador de corticotropina.
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
ES2160596T3 (es) Derivados de quinuclidina como antagonistas de la sustancia p.
MX9305294A (es) Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende.
ES2168260T3 (es) 3-aminoquinuclidinas sustituidas.
ES2138977T3 (es) Agonistas muscarinicos.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
ES2067322T3 (es) Lactamas substituidas en n utiles como antagonistas de colecistoquinina.
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
UY28150A1 (es) Agentes terapeuticos
ES2113368T3 (es) Antagonistas de serotonina.
ES2054872T3 (es) Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht.
MX9100308A (es) Derivados de quinuclidina
ES2116587T3 (es) Derivados espiroazaciclicos como antagonistas de la sustancia p.
ES2135414T3 (es) Antagonistas del receptor 5-ht4.
ES2158452T3 (es) Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos.
DE69113379D1 (de) 3-Aryl-4(3H)chinazolinone als CCK Antagonisten und diese enthaltende pharmazeutische Zusammensetzungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 475755

Country of ref document: ES